Initiate RAS Inhibitor Therapy and Consider SGLT2 Inhibitor
If the repeat UACR remains elevated after 3 months, start a renin-angiotensin system inhibitor (ACE inhibitor or ARB) at the highest tolerated dose, and strongly consider adding an SGLT2 inhibitor based on the degree of albuminuria and comorbidities 1.
Treatment Algorithm Based on Albuminuria Category
For Moderately Increased Albuminuria (UACR 30-300 mg/g or 3-30 mg/mmol)
- With diabetes: Start RASi (ACEi or ARB) - this is a strong recommendation 1
- Without diabetes: Consider starting RASi - this is a weaker recommendation but still suggested 1
- With UACR ≥200 mg/g (≥20 mg/mmol) OR heart failure: Add SGLT2 inhibitor regardless of diabetes status if eGFR ≥20 ml/min per 1.73 m² 1
For Severely Increased Albuminuria (UACR >300 mg/g or >30 mg/mmol)
- Start RASi immediately regardless of diabetes status - this is a strong recommendation 1
- Add SGLT2 inhibitor if eGFR ≥20 ml/min per 1.73 m² 1
Key Implementation Details
Dosing strategy: Use the highest approved dose of RASi that the patient tolerates, as clinical trial benefits were achieved at these doses 1. Don't settle for subtherapeutic dosing.
Monitoring after RASi initiation:
- Check BP, serum creatinine, and potassium within 2-4 weeks 1
- Continue RASi unless creatinine rises >30% within 4 weeks 1
- Manage hyperkalemia with potassium-lowering measures rather than stopping RASi when possible 1
SGLT2 inhibitor considerations:
- Continue even if eGFR drops below 20 ml/min per 1.73 m² once started 1
- The initial reversible eGFR decrease is not an indication to stop 1
- Withhold during prolonged fasting, surgery, or critical illness due to ketosis risk 1
Treatment Target and Monitoring
The goal is to achieve at least a 30% reduction in UACR from baseline, as this magnitude of reduction is associated with decreased risk of cardiovascular events, mortality, and CKD progression 2, 3. In a large real-world study of patients with CKD and type 2 diabetes, those achieving >30% UACR reduction had 16% lower risk of CKD progression, 7% lower mortality, and 7% lower cardiovascular events compared to stable UACR 3.
Conversely, a >30% increase in UACR was associated with 41% higher risk of CKD progression and 24% higher risk of both mortality and cardiovascular events 3. This underscores why persistent elevation after 3 months demands aggressive intervention.
Common Pitfalls to Avoid
- Don't use suboptimal RASi doses: The evidence base comes from trials using maximum approved doses 1
- Don't stop RASi prematurely for creatinine bumps <30%: This is expected and acceptable 1
- Don't withhold SGLT2i in advanced CKD: Continue even if eGFR falls below 20 once initiated 1
- Don't delay dual therapy: If UACR ≥200 mg/g, both RASi and SGLT2i should be started, not sequentially trialed 1